Abstract
Although cell-free protein synthesis has been practiced for decades as a research tool, only recently have advances suggested its feasibility for commercial protein production. This focused review, based on the 2005 Amgen Award lecture, summarizes the relevant progress from the Swartz laboratory. When our program began, projected costs were much too high, proteins with disulfide bonds could not be folded effectively, and no economical scale-up technologies were available. By focusing on basic biochemical reactions and by controlling cell-free metabolism, these limitations have been methodically addressed. Amino acid supply has been stabilized and central metabolism activated to dramatically reduce substrate costs. Control of the sulfhydral redox potential has been gained and a robust disulfide isomerase added to facilitate oxidative protein folding. Finally, simple scale-up technologies have been developed. These advances not only suggest production feasibility for pharmaceutical proteins, they also provide enabling technology for producing patient-specific vaccines, for evolving new enzymes to enable biological hydrogen production from sunlight, and for developing new and highly effective water filters. Although many challenges remain, this newly expanded ability to activate and control protein production holds much promise for both research and commercial applications.
Similar content being viewed by others
References
Calhoun KA, Swartz JR (2005) An economical method for cell-free protein synthesis using glucose and nucleoside monophosphates. Biotechnol Prog 21:1146–1153
Calhoun KA, Swartz JR (2005) Energizing cell-free protein synthesis with glucose metabolism. Biotechnol Bioeng 90:606–613
Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long term results of a clinical trial. Blood 89:3129–3135
Jewett MC, Swartz JR (2004) Mimicking the Escherichia coli cytoplasmic environment activates long-lived and efficient cell-free protein synthesis. Biotechnol Bioeng 86:119–126
Kim RG, Choi CY (2000) Expression-independent consumption of substrates in cell-free expression system from Escherichia coli. J Biotechnol 84:27–32
Kim DM, Swartz JR (2000) Oxalate improves protein synthesis by enhancing ATP supply in a cell-free system derived from Escherichia coli. Biotechnol Lett 22:1537–1542
Kim DM, Swartz JR (2001) Regeneration of adenosine triphosphate from glycolytic intermediates for cell-free protein synthesis. Biotechnol Bioeng 74:309–316
Kim DM, Swartz JR (2004) Efficient production of a bioactive, multiple disulfide-bonded protein using modified extracts of Escherichia coli. Biotechnol Bioeng 85:122–129
Knapp K, Swartz JR (2004) Cell-free production of active E. coli thioredoxin reductase and glutathione reductase. FEBS Lett 559:66–70
Liu D, Zawada J, Swartz JR (2005) Streamlining Escherichia coli S30 extract preparation for economical cell-free protein synthesis. Biotechnol Prog 21:460–465
Michel-Reydellet N, Calhoun K, Swartz JR (2004) Amino acid stabilization for cell-free protein synthesis by modification of the E. coli genome. Metab Eng 86:19–26
Michel-Reydellet N, Woodrow K, Swartz J (2005) Increasing PCR fragment stability and protein yields in a cell-free system with genetically modified Escherichia coli extracts. J Mol Microbiol Biotechnol 9:26–34
Narindrasorasak S, Bridger WA (1978) Probes of the structure of phosphoenol pyruvate synthetase: effects of a transition state analogue on enzyme conformation. Can J Biochem 56:816–819
Nirenberg MW, Matthaei JH (1961) The dependence of cell-free protein synthesis in E.coli upon naturally occurring or synthetic polyribonucleotides. Proc Natl Acad Sci USA 47:1588–1602
Posewitz MC, King PW, Smolinski SL, Zhang L, Seibert M, Ghirardi ML (2004) Discovery of two novel radical S-adenosylmethionine proteins required for the assembly of an active [Fe] hydrogenase. J Biol Chem 279:25711–2572
Ryabova LA, Vinokurov LM, Shekhovtsova EA, Alakhov YB, Spirin AS (1995) Acetyl phosphate as an energy source for bacterial cell-free translation systems. Anal Biochem 226:184–186
Tao MH, Levy R (1993) Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755–759
Underwood K, Swartz JR, Puglisi JD (2005) Quantitative polysome analysis identifies limitations in bacterial cell-free protein synthesis. Biotechnol Bioeng 91:425–435
Voloshin AM, Swartz JR (2005) Efficient and scalable method for scaling up cell-free protein synthesis systems in batch mode. Biotechnol Bioeng 91:516–521
Yang J, Kanter G, Voloshin A, Levy R, Swartz JR (2004) Expression of active murine granulocyte-macrophage colony-stimulating factor in an Escherichia coli cell-free system. Biotechnol Prog 20:1689–1696
Yang J, Kanter G, Voloshin A, Michel-Reydellet N, Velkeen H, Levy R, Swartz JR (2005) Rapid expression of vaccine proteins for B cell lymphoma in a cell-free system. Biotechnol Bioeng 89:503–511
Yin G, Swartz JR (2004) Enhancing multiple disulfide-bonded protein folding in a cell-free system. Biotechnol Bioeng 86:188–195
Zawada J, Swartz J (2005) Maintaining rapid growth in moderate-density Escherichia coli fermentations. Biotechnol Bioeng 89:407–415
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Swartz, J. Developing cell-free biology for industrial applications. J IND MICROBIOL BIOTECHNOL 33, 476–485 (2006). https://doi.org/10.1007/s10295-006-0127-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10295-006-0127-y